STOCKS TELEGRAPH

Tag: NASDAQ:SCNX

  • Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light

    Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light

    The stock price of Scienture Holdings, Inc. (NASDAQ: SCNX) saw a significant increase, rising 23.79% to $3.07 during pre-market activity. This spike comes after a major regulatory change involving one of its medications.

    FDA Gives Arbli Oral Suspension Approval

    The FDA has approved SCN-102, a losartan potassium oral suspension (10 mg/mL) produced by Scienture, LLC, a fully owned subsidiary of Scienture Holdings (SCNX), to be sold under the brand name Arbli.

    Arbli is used to treat hypertension in patients six years of age and older, manage diabetic nephropathy in some patients with type 2 diabetes, and lower the risk of stroke in those with hypertension and left ventricular hypertrophy. However, Arbli is the first ready-to-use oral liquid version of losartan that has received FDA approval and is offered for sale in the United States.

    A New Composition for Improved Patient Comfort

    Arbli is a patented development in losartan medication that provides a customized liquid formulation for patients who need or want an alternative to tablets. Arbli guarantees precise dosage, safety, and consistency by doing away with the necessity for tablet crushing and impromptu compounding. The product has secured two patents from the U.S. Patent and Trademark Office (USPTO), which are anticipated to be listed in the FDA’s Orange Book.

    Market Impact and Future Prospects

    One of the most often recommended medications for hypertension is still losartan, an angiotensin receptor blocker (ARB). The only formulations currently on the market are solid oral dose forms, which medical professionals frequently combine to create liquid solutions. Arbli distinguishes itself as the first commercially available liquid formulation requiring no additional preparation while offering extended shelf stability at room temperature.

    According to IQVIA data (MAT December 2024), losartan recorded total annual U.S. sales of approximately $292 million with 68 million prescriptions issued. The approval of Arbli underscores Scienture’s strategic focus on developing high-value pharmaceutical products tailored to underserved patient needs.

    With this milestone marking its first FDA-approved proprietary brand, Scienture (SCNX) plans to launch Arbli commercially in Q3 2025, broadening its portfolio of specialty treatments.

  • Scienture (SCNX) Soars In Pre-Hour Trading After Strategic Business Development

    Scienture (SCNX) Soars In Pre-Hour Trading After Strategic Business Development

    Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are on a significant rise following the announcement of a key commercialization agreement. As of the latest premarket check, SCNX stock had surged 26.69%, reaching $2.80. The sharp increase reflects investor confidence in the company’s strategic initiative to enhance its commercial presence in the pharmaceutical sector.

    Exclusive U.S. Rights for REZENOPY

    Scienture Holdings announced that Summit Biosciences Inc., a division of Kindeva Drug Delivery L.P., and Scienture, LLC, a wholly owned subsidiary, have reached a final agreement. Through this collaboration, SCNX will have the only right to introduce and sell REZENOPY (naloxone HCl) Nasal Spray in the US.

    The opioid antagonist was approved by the FDA on April 19, 2024, and is intended to successfully prevent opioid overdoses. The deal states that Scienture would maintain ownership of the new drug application (NDA), while Kindeva will be in charge of REZENOPY’s production and commercial supply.

    In order to guarantee broad availability, SCNX will also oversee the product’s marketing, sales, and distribution throughout the United States by utilizing its infrastructure for commercial operations.

    Increased Efficiency in Addressing the Opioid Epidemic

    REZENOPY stands out as the strongest naloxone HCl formulation on the market right now. Its increased effectiveness against extremely strong opioids highlights how important it is to combating the current drug problem.

    Scienture wants to work with advocacy groups, legislators, and medical experts to raise awareness, enhance education, and expedite distribution in light of the rising number of overdose-related deaths.

    Market Prospects and Industry Influence

    First responders and medical professionals rely heavily on the nasal administration of naloxone HCl because of its efficacy, accessibility, and ease of usage. The U.S. naloxone market produced $189 million in total yearly sales with a unit volume of 10 million, according to IQVIA statistics (MAT December 2024).

    Scienture is well-positioned to play a significant part in increasing access to this necessary drug with the commercial launch of REZENOPY, reaffirming its leadership in tackling public health issues.